SEARCH

SEARCH BY CITATION

References

  • 1
    Miners JO , Birkett DJ . Cytochrome P450 CYP2C9: an enzyme of major importance in human drug metabolism . Br J Clin Pharmacol 1998 ; 45 : 525538 . DOI: 10.1046/j.1365-2125.1998.00721.x
  • 2
    Takahashi H , Kashima T , Nomizo Y , et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes . Clin Pharmacol Ther 1998 ; 63 : 519528 .
  • 3
    Mamiya K , Iiri I , Shimamoto J , et al. The effects of a genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult epileptic patients; studies in sterioselective hydroxylation and pharmacokinetic . Epilepsia 1998 ; 39 : 13171323 .
  • 4
  • 5
    Stubbins MJ , Harries LW , Smith G , Tarbit MH , Wolf CR . Genetic analysis of the cytochrome P450 CYP2C9 locus . Pharmacogenetics 1996 ; 6 : 429439 .
  • 6
    Sullivan-Klose TH , Ghanayem BI , Bell DA , et al. The role of the CYP2C9-leu359 allelic variant in the tolbutamide polymorphism . Pharmacogenetics 1996 ; 6 : 341349 .
  • 7
    London SJ , Daly AK , Leathart JB , Navidi WC , Idle JR . Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles country, California . Pharmacogenetics 1996 ; 6 : 527533 .
  • 8
    Yasar ü Eliasson E , Dahl ML , Johansson I , Ingelman-Sundberg M , Sjöqvist F . Validations of methods for CYP2C9 genotyping: frequency of mutant alleles in a Swedish population . Biochem Biophys Res Comm 1999 ; 254 : 628631 .
  • 9
    Brøsen K . Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry . Ther Drug Monit 1996 ; 18 : 393396 .
  • 10
  • 11
    deMorais SMF , Wilkinson GR , Blaisdell J , Nakamura K , Meyer UA , Goldestein JA . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans . J Biol Chem 1994 ; 269 : 1541915422 .
  • 12
    deMorais SMF , Wilkinson GR , Blaisdell J , Nakamura K , Meyer UA , Goldestein JA . Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin hydroxylase in Japanese . Mol Pharmacol 1994 ; 48 : 594598 .
  • 13
    Griese EU , Ilett KF , Kitteringham NR , et al. Allele and genotype frequencies of polymorphic cytochromes P450 2D6, 2C19 and 2E1 in Aborigines from Western Australia . Pharmacogenetics 2001 ; 11 : 6976 .
  • 14
    Umeno M , McBridge OW , Yang CS , Gelboi HV , Gonzalez FJ . Human ethanol-inducible P450IIE1: complete gene sequence; promoter characterization, chromosome mapping and cDNA-directed expression . Biochemistry 1988 ; 27 : 90069013 .
  • 15
    Kim RB , O'Shea D . Interindividual variability of chlorzoxazone 6 hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms . Clin Pharmacol Ther 1995 ; 57 : 645655 .
  • 16
    Watanabe J , Hayashi S , Kawajiri K . Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′ flanking region . J Biochem 1994 ; 116 : 321326 .
  • 17
    Anwar WA , Abdel-Rahman SZ , El-Zein RA , Mostafa HM , Au WW . Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients . Carcinogenesis 1996 ; 17 : 19231929 .
  • 18
    Gonzalez FJ , Fernandez-Salguero P . Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency . Trends Pharmacol Sci 1995 ; 16 : 325327 .
  • 19
    Lu Z , Zhang R , Diaasio RB . Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy . Cancer Res 1993 ; 53 : 54335438 .
  • 20
    Morsman JM , Sludden J , Ameyaw MM , et al. Evaluation of dihydropyrimidine dehydrogenase activity in southwest Asian, Kenyan and Ghanaian populations . Br J Clin Pharmacol 2000 ; 50 : 269272 . DOI: 10.1046/j.1365-2125.2000.00242.x
  • 21
    Collie-Duguid ESR , Etienne MC , Milano G , Mcleod HL . Known variant DPYD allele don't explain DPD deficiency in cancer patients . Pharmacogenetics 2000 ; 10 : 217223 .
  • 22
    Hiratsuka M , Agatsuma Y , Omori F , et al. High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay . Biol Pharm Bull 2000 ; 23 : 11311135 .
  • 23
    Kato S , Shields PG , Caporaso NE , et al. Cytochrome P4502E1 genetic polymorphisms, racial variation, and lung cancer risk . Cancer Res 1992 ; 52 : 67126715 .
  • 24
    Ridge SA , Sludden J , Brown O , et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects . Br J Clin Pharmacol 1998 ; 46 : 151156 .
  • 25
    Aynacioglu AS , Brockmöller J , Bauer S , et al. Frequency of cytochrome P4502C9 variants in a Turkish population and functional relevance for phenytoin . Br J Clin Pharmacol 1999 ; 48 : 409415 .
  • 26
    Nasu K , Kubota T , Ishizaki T . Genetic analysis of CYP2C9 in a Japanese population . Pharmacogenetics 1997 ; 7 : 405409 .
  • 27
    Yoon YR , Shon JH , Kim MK , et al. Frequency of cytochrome P4502C9 mutant alleles in a Korean population . Br J Clin Pharmacol 2001 ; 51 : 277280 .
  • 28
    Yamazaki H , Inoue K , Chiba K , et al. Comparitive studies on the catalytic roles of Cytochrome P4502C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes . Biochem Pharmacol 1998 ; 56 : 243251 .
  • 29
    Takahashi H , Kashima T , Nomo S , et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes . Pharmacogenetics 1998 ; 8 : 365373 .
  • 30
    Bertilsson L , Dahl ML , Ingelman-Sundberg M , Johansson I , Sjoqvist F . Interindividual and interethnic differences in polymorphic drug oxidation-implications for drug therapy with focus on psychoactive drugs . In Advances in Drug Metabolism in Man , eds Pacifici GM , Fracchia GN. DGXII-E-4eur1549 EN, EC. Office For Official Publications of the European communities , Luxembourg , 1995 ; 85136 .
  • 31
    Kaneko A , Berqvist Y , Taleo G , Kobayakawa T , Ishizaki T , Björkman A . Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations . Pharmacogenetics 1999 ; 9 : 317326 .
  • 32
    Chang M , Dahl ML , Tybring G , Gotharson E , Bertilsson L . Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype . Pharmacogenetics 1995 ; 5 : 358363 .
  • 33
    Furuta T , Ohashi K , Kamata T , et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer . Ann Intern Med 1998 ; 129 : 10271030 .
  • 34
    Xie HG , Stein CM , Kim RB , Wilkinson GR , Flockhart DA , Wood AJ . Allelic, genotypic and phenotyping distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world . Pharmacogenetics 1999 ; 9 : 539549 .
  • 35
    Goldstein JA , Ishizaki T , Chiba K , et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations . Pharmacogenetics 1997 ; 7 : 5964 .
  • 36
    Jurima-Romet M , Goldstein JA , LeBelle M , et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population . Pharmacogenetics 1996 ; 6 : 329339 .
  • 37
    Bathum L , Andersen-Ranberg K , Boldsen J , Brøsen K , Jeune B . Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity: role of CYP2D6 and CYP2C19 in longevity . Eur J Clin Pharmacol 1998 ; 54 : 427430 .
  • 38
    Yamada H , Dahl M-L , Lannfelt L , Vitainen M , Winblad B , Sjöqvist F . CYP2D6 and CYP2C19 genotypes in an elderly Swedish population . Eur J Clin Pharmacol 1998 ; 54 : 479481 .
  • 39
    Bröckmollr J , Rost KL , Gross D , Schenkel A , Roots I . Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G to A splice site mutation . Pharmacogenetics 1995 ; 5 : 8088 .
  • 40
    Ruas JR , Lechner MC . Allele frequency of CYP2C19 in a Portuguese population . Pharmacogenetics 1997 ; 7 : 333335 .
  • 41
    Hoskin JM , Shenfield GM , Gross AS . Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population . Br J Clin Pharmacol 1998 ; 46 : 499504 . DOI: 10.1046/j.1365-2125.1998.00807.x
  • 42
    Herrlin K , Massele AY , Jande M , et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype . Clin Pharmacol Ther 1998 ; 64 : 391401 .
  • 43
    Lamba JK , Dhiman RK , Kohli KK . CYP2C19 genetic mutations in North Indians . Clin Pharmacol Ther 2000 ; 68 : 328335 .
  • 44
    Persson I , Aklillu E , Rodrigues F , Bertilsson L , Ingelman-Sundberg M . S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians . Pharmacogenetics 1996 ; 6 : 521526 .
  • 45
    Dandara C , Masimirembwa CM , Magimba A , et al. Genetic polymorphism of CYP2D6, CYP2C19 in East, Southern African populations including psychiatric patients . Eur J Clin Pharmacol 2001 ; 75 : 1117 .
  • 46
    Rannug A , Alexandrie A-K , Persson I , Ingelman-Sundberg M . Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance . JOEM 1995 ; 37 : 2536 .
  • 47
    Wei X , Elizonodo G , Sapone A , et al. Characterization of the human dihydropyrimidine dehydrogenase gene . Genomics 1998 ; 51 : 391400 .
  • 48
    Verken P , van Kuilenburg ABP , Meinsma R , et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency . J Inher Metab Dis 1996 ; 19 : 645654 .
  • 49
    van Kuilenburg ABP , Verken P , Beex LVAM , de Abreu RA , van Gennip AH . Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G to A point mutation . J Inher Metab Dis 1998 ; 21 : 280284 .
  • 50
    Verken P , van Kuilenburg ABP , Meinsma R , van Gennip AH . Identification of novel points mutations in the dihydropyrimidine dehydrogenase gene . J Inher Metab Dis 1997 ; 20 : 335338 .
  • 51
    Ridge SA , Sludden J , Wei X , et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer . Br J Cancer 1998 ; 77 : 497500 .